VIVUS, Inc. (NASDAQ:VVUS) announced that Shari Belafonte is teaming up with the company to educate American adults about seeking medical treatment for chronic weight management when diet and physical activity alone have not been successful. Ms. Belafonte, an actress, model, photographer, writer, singer and daughter of famed musician and actor Harry Belafonte, knows that the impact of being overweight is more than superficial. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -4.11% in last session and finished the day at $5.60. Traded volume was 2.77million shares in the last session and the average volume of the stock remained 3.04million shares. The beta of the stock remained 1.28. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

Dipexium Pharmaceuticals, LLC (NASDAQ:DPRX), a late stage biopharmaceutical company developing Locilex™ (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share. Dipexium Pharmaceuticals, LLC (NASDAQ:DPRX) dropped -8.29 percent to $9.95 Monday on volume of 64.76K shares. Dipexium Pharmaceuticals, LLC (NASDAQ:DPRX) has a market capitalization of $76.45million.

TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) announced that J. Kevin Buchi, President and Chief Executive Officer, is the recipient of the 2014 Frank Baldino Jr. CEO of the Year Award awarded by Pennsylvania Bio, the statewide life sciences industry trade association. Mr. Buchi was honored at PA Bio’s Annual Dinner and Awards Celebration and Ceremony on March 12, 2014 in Philadelphia. Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)’s stock on Mar 24, 2014 reported a decrease of -7.84% to the closing price of $6.82. Its fifty two weeks range is $6.75 -$14.75. The total market capitalization recorded $151.92million. The overall volume in the last trading session was 134,233.00million shares. In its share capital, TLOG has 19.28million outstanding shares.

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions. Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has granted the underwriters an option for a period of 45 days to purchase, at the public offering price less the underwriting discount, up to 425,610 additional ordinary shares to cover over-allotments. On Monday, shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) dropped -11.66% to close the day at $11.97.